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Summary.-Asimple rapid micro-agglutination testfor detecting sensitized lympho-
cytes from human peripheral blood is described: the poly-L-lysine (PLL) 3400
agglutination test of lymphocytes (PAL test). The incubation of lymphocytes from 30
cancer patients, 30 patients with non-malignant disease and 40 healthy controls with
PLL (mol. wt 3400) is evaluated. The test was positive in 830; of malignant and 20%
of non-malignant cases. All healthy controls were negative.
Other peptides tested showed no significant difference in reaction between malig-
nant and non-malignant diseases. The mechanism of detection of sensitized lympho-
cytes from patients with malignant disease through agglutination induced by PLL
3400 is discussed.
THERE have been reports of the inctu-
bation ofhuman peripheral blood lympho-
cytes from cancer patients with basic
protein of myelin in the presence of
guinea-pig macrophages, in order to diag-
nose malignant disease in humans. Dif-
ferent techniques have been tried in
order to identify sensitized lymphocytes.
This can be done either indirectly, by
detection of released lymphokines as in
the MEM test established by Field and
Caspary (1970) and improved by Porzsolt,
Tautz and Ax (1975) or directly, by
making visible the interaction of lympho-
cytes with basic protein as was done by
Sabolovic et al. (1975). These methods
identify sensitized human blood lympho-
cytes by changes on their cell suirfaces.
The alteration of the lymphocyte surface
presupposes a special interaction with
basic proteins, which couild be shown by
the reduced electrophoretic mobility of
sensitized blood lymphocytes and by
simple histone F2al micro-agglutination
(Sabolovic et al., 1975).
The aim of our investigation was to
simplify and standardize these aggluti-
nation techniques by using defined syn-
thetic peptides, in particular poly-L-
lysine 3400 (PAL test), to detect sensitized
lymphocytes in patients with malignant
diseases.
MATERIALS AND AIETHODS
Lymphocytes from 5 ml of heparinized
blood were isolated by a single-step discon-
tinuous Ficoll-Isopaque(R) gradient, as des-
cribed by English and Anderson (1974).
Synthetic peptides were purchased from
Miles, D-4000 Frankfurt and Sigma, D-8000
Miinchen. The lymphocytes wNere washed and
diluted with Hanks' solution (Flowvi Labora-
tories) to a concentration of 6 x 106/ml.
The lymphocyte suspension must be as pure
as possible. Non-lymphoid cells and erythro-
cytes will disturb the test through non-specific
agglutination. Basic polypeptide fractions
were dissolved in 0-145 M NaCl, pH 7 0, at a
concentration of 0 05 mg/ml.
Equal volumes of lymphocyte suspension
and peptide solution weremixed; for example,
1 ml of 6 x 106/ml lymphocytes and 1 ml of
0-05mg/ml basic peptide. Serial dilutions of
2 ml of the reaction mixture were distributed
on microplates containing 20 pil per wN-ell
(Greiner, C. A., D-7440 Niirtingen). The
plates wA,ere incubated immediately after-PAL TEST FOR MALIGNANT DISEASES
FIG. 1.-Microagglutination of lymphocytes
positive reaction. Poly-L-lycine 3400:
0-05 mg/ml per 6 x 106 lymphocytes.
wards for 30 min at 37°C under atmospheric
conditions and examined under a bright-
field microscope at 100 x magnification.
Results were read blind by two independent
persons. Positive reactions were characterized
by more than 5 lymphocytes at different
levels being in direct contact with each other.
Micro-agglutination of lymphocytes, positive
and negativ-e reactions are shown in Figs. 1
and 2.
RESULTS
In the test described above the follow-
ing basic peptides were examined:
Poly-L-Lysine mol. wt 230,000; 70,000;
56,600; 32,000;
15,000; 3400;
199,400; 150,000;
Poly-D-Lysine mol. wt 199,400; 150,000;
70,000
FIG. 2.-Microagglutination of lymphocytes:
negative reaction. Treatment as in Fig. 1.
Poly-DL-Lysine mol. wt 64,000; 16,400
Poly-L-
Arginine mol. wt 17,000; 10,000
Poly-Lo-
Ornithine mol. wt 53,000; 21,000
L-Leucyl-
Glycyl-
Glycine mol. wt 945
Gly-L-His-L-
Lys mol. wt 339
L-Lysine mol. wt 182-7
D-Lysine mol. wt 182-7
Peptide solubility in physiological media
and a structural similarity to histone
F2al were the preconditions for the
selection of the peptides used. Histone
F2al is a component of basic nuclear
protein, consisting mainly of arginine,
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TABLE I.-Basic Polypeptides Tested in the Lymphocyte Agglutination Test
Concentrations mg/ml
I~
Substance
Poly-L-Lysine
(PLL)
Poly-D-Lysine
Poly-DL-Lysine
Poly-L-Arginine
Poly-L-Ornithine
Gly-L-His-L-Lys
L-Leucyl-Glycyl-Glycine
L-Lysine
D-Lysine
Mol. wt Controls
1-0 0-5 0-1 0-05 0-01
230,000
70,000
56,000 J
32,000
15,000 r
3,400
199,000
150,000
70,000
64,000
16,400
17,000
10,000
53,000
21,000
339
245
182-7
182-7
Patients with malignant tumours
-
1-0 0 5 0-1 0 05 0-01
no specific reaction
± ± +1- +1- +/_ ± ±±I- - _-
++± ± ±
+ ± + ± ±l_
no specific reaction
no specific reaction
no specific reaction
limited specific reaction
no reaction
TABLE II.-Lymphocyte Agglutination Induced by Poly-L-Lysine (PLL) 3400 (0-05
mg/ml per 6 X 106 Lymphocytes)
Diagnoses pH: 6-5 7-0 7-4 8-0
0-1 0-05 0-1 0-05 0-1 0-05 0-1 0-05
Non-malignant
disease*
Malignant + + + + + + + +
tumourt
Healthy control
* Struma
t Cancer of the ovary
lysine and glycine with a molecular
weight of 13,500 (Wilhelm, Spelsberg and
Hnilica, 1971).
The most evident differences in the
reactionofhumanperipheralbloodlympho-
cytes between healthy donors and malig-
nant donors occurred in the presence of
PLL with a molecular weight of 3400.
Lymphocytes from patients with malig-
nant tumours were agglutinated in con-
trast to lymphocytes from healthy sub-
jects at concentrations of 0-1 mg/ml and
0-05 mg/ml.
D-Lysine, L-lysine, gly-L-lys and L-
leucyl-glycyl-glycine reacted neither with
lymphocytes of healthy subjects nor
withlymphocytes ofpatients with a malig-
nancy. The otherpeptides listed abovelead
to an agglutination by control persons as
well as by patients suffering from malig-
TABLE III.-Agglutination of Peripheral
Human Lymphocytes after Incubation with
Poly-L-Lysine (PLL) 3400 at a Concen-
tration of 0-05 mg/ml/6 x 106 Lymphocytes.
Total Negative Positive
Malignant Tumours * 30 5 ( 17%) 25 (83%)
Non-malignant
diseases 30 24 ( 80%) 6 (20%)
Healthy controls 40 40 (100%) 0
* Cancer of the stomach, breast, colon, corpus
uteri, lung, pancreas, rectum, as well as malignant
melanoma and fibrosarcoma.
nant processes. The concentrations used
were 1, 0-5, 0-1 and 0-05 mg peptide/ml
of 0-145 M NaCl, pH 7-0 (Table I).
The reaction is independent of the pH
within the physiological range 6-5-8-0
(Table II).
Table III shows the rate of agreement
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between the positive reactions of lympho-
cytes with Poly-L-Lysine, molecular
weight 3400 and the presence ofmalignant
tumours.
There were no agglutination reactions in
the 40 healthy controls. In the group of
patients with malignant diseases con-
sisting of carcinomas, melanomas and
sarcomas the lymphocytes showed positive
reactions in 830% of the cases. Carcinomas
alone had a positive rate of 930. For
additional controls, patients with non-
malignant diseases were examined: a 2000
positive rate was found.
Chronic inflammations of the colon
(,olitis ulcerosa) and the kidnev (pye-
lonephritis) might be the reason for these
false positive reactions. The diagnosis of
patients with negative results in the group
of subjects with benign diseases were:
ulcus venitriculi, haemorrhoids, diabetes
mellitus, bronchitis, hypertension, hypo-
gonadism and coronary heart infarction.
DISCUSSION
How is the apparent selectivity of
lymphocyte agglutination by PLL to be
explainedi in cases of malignant dis-
orders? In the MEM test (Field and
Caspary, 1970) lymphocytes sensitized
against determinants of tumour antigens
were detectable. The reaction was not
influenced by substitution ofEF (encepha-
litogenic factor) by histone F2al (Johns et
al., 1973). These results indicate that a
structural relationship necessary for im-
munological cross-reaction between EF,
histone F2al and some antigenic deter-
minants of tumour antigens may exist.
With histone F2al it is indeed possible to
recognize sensitized lymphocytes by ag-
glutination (Sabolovic et al., 1975). It has
been shown that PLL with a mol. wt of
3400 has the ability to react in the same
wav as histone F2ai. The reason for this
phenomenon may be that the nuclear
basic protein histone F2al consists of about
1000 lysine beside several other amino-
acids (WVilhelm et al., 1971). Sabolovic et al.
(1975) already tried to substitute histone
F2al by using its main components poly-
arginin or PLL, but the information on
the use of poly-arginine was inadequate.
These authors also tried unsuccessfully to
use PLL. The reason might be that their
attention was not focused on molecular
weight.
We obtained similar results too, using
different PLLs, until we used PLL of the
short-chain type (i.e. 3-5000 mol. wt).
If the agglutination is a specific inter-
action between the antigen and a specific
receptor, then related structures in EF,
histone F2al and tumour antigens should
include PLL 3400. Some evidence for
this hypothesis lies in the ability of PLL
3400 to substitute for EF in the MEM test.
The same cell population is likely to be
detected in the MEM test and in the PLL-
induced agglutination of lymphocytes
(PAL test). It is difficult to explain why
all the other basic peptides and PLL with
higher mol. wt are able to agglutinate
both lymphocytes from both controls and
patients with neoplastic disease. One may
speculate about higher mol. wt poly-
peptides resembling ubiquitous antigenic
structures, whereas malignant cells have in
common only reduced antigenic structures
which are analogous to PLL 3400. This
may cause the selective recognition and
agglutination.
The charge and the molecular weight of
the peptides offer a second possibility of
interpretation. PLL with higher mol. wt
acts as a non-specific binding agent for
erythrocytes and tumour cells on plastic
surfaces (Kedar et al., 1974). Presumably
this effect depends on the net negative
surface charge of cells and the positive
charge of basic peptides and ionic electro-
lytes, as discussed by Currie and Bagshawe
(1967).
Lymphocytes have electro-negative cell-
surface properties. In an electric field one
can differentiate between two cell popula-
tions: T lymphocytes migrate in the
directionoftheanode at ahigherspeedthan
B lymphocytes (Ambrose, James and
Lowids, 1956; Ruhenstroth-Bauer and
Luicke-Huhle, 1968; Sundaram, Phondke
and Ambrose, 1967; Hannig and Zeiller,
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1969; Sabolovic, Sabolovic anld Dumont,
1972).
In 1975 Plagne et al. reported the
appearance of additional slowly migrating
peripheral lymphocytes in malignant dis-
ease; theirfunction could not be explained.
Perhaps these less negative subpopula-
tions of additionally recruited T lympho-
cytes are the cells which could be detected
by the PLL-induced agglutination test
(PAL test). We suggest as an explanation
that the binding capacity of PLL with
mol. wt of 3400 is strong enough to bring
these less negatively charged cells into
contact with each other, thus leading to
agglutination. Intense repulsion forces of
more strongly negatively charged lympho-
cytes, such as from healthy persons, can
be overcome only with larger molecules of
the higher-mol. wt PLL. The agglutination
is not, however, a phenomenon depen-
dent on charge. The peptide-lymphocyte
interaction was not influenced by the pH
of the reaction medium.
A lot of research is needed to find out
about the reaction mechanism and the
reason for the interaction of lymphocytes
with basic peptides, especially with PLL
3400. The molecule of PLL 3400 possibly
represents a synthetic structure "cross-
reacting" in part with "some tumour-
specific or tumour-associated antigens",
which were suggested byJohns etal. (1973)
in connection with the "encephalithogenic
antigen", and histone F2al.
At present the most important thing to
be done is to corroborate the micro-
agglutination induced by PLL 3400 and
malignant growth by screening a large
population of patients.
The authors wish to express their
appreciation to Miss S. Schottler for her
valuable suggestions for improving the
procedure.
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